View Future GrowthCosmo 과거 순이익 실적과거 기준 점검 0/6Cosmo은 연평균 16.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 4.9%의 비율로 증가했습니다. 매출은 연평균 17.1%의 비율로 증가했습니다.핵심 정보16.94%순이익 성장률17.97%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률14.12%매출 성장률17.07%자기자본이익률-1.08%순이익률-6.19%최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트Reported Earnings • Jul 29First half 2026 earnings released: €0.28 loss per share (vs €0.13 loss in 1H 2025)First half 2026 results: €0.28 loss per share (further deteriorated from €0.13 loss in 1H 2025). Revenue: €50.2m (down 2.9% from 1H 2025). Net loss: €4.75m (loss widened 137% from 1H 2025). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.공고 • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026공고 • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025공고 • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공고 • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024모든 업데이트 보기Recent updates공고 • Aug 13Cosmo Pharmaceuticals Reports 12-Month Phase 3 Results for Clascoterone 5% Topical Solution in Male Androgenetic AlopeciaCosmo Pharmaceuticals reported recent Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia. According to Cosmo Pharmaceuticals, the 12-month results from its SCALP 1 and SCALP 2 Phase 3 program showed a safety and tolerability profile comparable to vehicle and continued hair growth in patients who remained on treatment through one year. The company reported a statistically significant 2.39-fold improvement in target area hair count among patients who stayed on clascoterone for the full 12 months, compared with those who received the drug for six months and were then switched to vehicle. The program enrolled 1,465 men across 51 centers in the United States and Europe. Androgenetic alopecia, or male pattern hair loss, is the most common cause of hair loss in men. Cosmo reports that it affects roughly 40% of men worldwide and about 65 million men in the United States, yet the category has seen limited pharmaceutical innovation for decades. Clascoterone is designed to locally inhibit androgen receptor signaling in the scalp, targeting one of the biological drivers of follicle miniaturization. According to Cosmo, if approved it would be the first treatment with a novel mechanism of action for male androgenetic alopecia in more than 30 years. Clascoterone is the same active ingredient used in Winlevi, an approved topical acne treatment, which gives the molecule an established dermatologic safety record. The one-year findings come from an extension phase with a specific structure. Only patients who reported a positive response on the study's patient-reported outcome survey during the first six months continued into the second six-month period, where they were re-randomized to stay on clascoterone or switch to vehicle. That design is common in long-term dermatology trials and is consistent with FDA guidance on evaluating durability, but it means the 12-month results describe patients who had already shown a response rather than everyone who started treatment. Cosmo has said it is preparing regulatory submissions, with a U.S. FDA filing planned for early 2027, and intends to submit the full dataset for peer-reviewed publication and presentation at dermatology meetings.Reported Earnings • Jul 29First half 2026 earnings released: €0.28 loss per share (vs €0.13 loss in 1H 2025)First half 2026 results: €0.28 loss per share (further deteriorated from €0.13 loss in 1H 2025). Revenue: €50.2m (down 2.9% from 1H 2025). Net loss: €4.75m (loss widened 137% from 1H 2025). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.공고 • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.공고 • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026공고 • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.공고 • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).공고 • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.공고 • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025공고 • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025공고 • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.공고 • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.New Risk • Mar 24New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin).Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공고 • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024공고 • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024공고 • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.Reported Earnings • Jul 28First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 24Upcoming dividend of €1.05 per share at 2.0% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%).Reported Earnings • Mar 25Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021)Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.공고 • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CHF42.90, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.Reported Earnings • Aug 02First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Executive Departure • Jun 04Non-Executive Director Hans Tanner has left the companyOn the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.Reported Earnings • Mar 27Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 06New 90-day high: CHF87.80The company is up 10.0% from its price of CHF79.90 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 11% over the same period.공고 • Dec 04Cosmo Pharmaceuticals Announces Licence of Lumeblue (Methylene Blue MMX) China Rights to China Medical System Holdings LtdCosmo Pharmaceuticals N.V. announced that it has licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy. CMS is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China. CMS concentrates on innovative products that are global first-in-class or with the best efficacy or best cost-effectiveness in the same class due to their innovative formulations or drug delivery systems, and has built up an innovative pipeline with great market potential and competitive differentiation advantages at relatively high innovation level, covering various therapeutic fields. Meanwhile, CMS has proven and successful experience in drug promotion for over two decades, and established a professional, compliant and efficient academic promotion system. CMS is listed on the Main Board of the Stock Exchange of Hong Kong. CMS will pay Cosmo a USD 5m upon the earlier of (a) the execution of a supply agreement or (b) the forty-fifth (45th) day from the execution of this agreement, plus royalties and potential regulatory and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™.공고 • Dec 01Cosmo Pharmaceuticals Appoints H. Jurgen Lenz as New Chief Medical OfficerCosmo Pharmaceuticals N.V. announced that Dr. H. Jurgen Lenz, MD, has been appointed Chief Medical Officer starting from December 1st, 2020. Dr. Lenz is a gastroenterologist and is Chief of the Division of Gastroenterology at Scripps Memorial Hospital, La Jolla, CA, USA. He is member of the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE) and American Association for the Study of Liver Diseases (AASLD).공고 • Nov 24Cosmo Pharmaceuticals N.V. Announces Senior Leadership Changes, Effective January 1, 2021Cosmo Pharmaceuticals N.V. announced two senior leadership changes which will take effect from the 1st of January 2021. Mr. Giuseppe Cipriano, the current COO, will be appointed to the position of Chief People Officer of Cosmo and will take the lead for all aspects related to managing human resources and industrial relations. Mr. Cipriano has been COO since 2001. Mr. Marco Lecchi, the current Head of Internal Audit, will be appointed to the position of Chief Operating Officer. Mr. Lecchi has been with Cosmo since 2001 and served as Deputy CFO since 2007 prior to his appointment as Head of Internal Audit in 2016.공고 • Nov 19Cosmo Pharmaceuticals Announces Expansion of Agreement with Dr. Falk Pharma for Rifamycin SV MMXCosmo Pharmaceuticals N.V. announced that it has expanded its existing license agreement with Dr. Falk Pharma Gmbh ("Dr. Falk") to include Rifamycin SV MMX in the new 600mg formulation currently tested in the IBS-D indication. Under the agreement with Dr Falk, Cosmo will receive a further &euro2m down-payment plus reimbursement of a portion of the expenses borne for the development of the 600mg formulation plus a supply price which incorporates a high double-digit percentage of sales. Dr. Falk will also bear a portion of the future costs for the ongoing developments. Rifamycin SV MMX 200mg is already approved in the US and EU for the treatment of travelers' diarrhea and it is licensed to Dr. Falk for the EU and other countries and is marketed under the brand name Relafalk®, whereas it is licensed to RedHill BioPharma Ltd. for the US where it is marketed under the brand name Aemcolo®. A Phase II clinical study with Rifamycin 600mg in IBS-D indication is currently ongoing and results are expected by year end.매출 및 비용 세부 내역Cosmo가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BATS-CHIXE:COPNZ 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 26103-6303131 Mar 26103-5283331 Dec 25104-4273430 Sep 2514328303630 Jun 2518260343931 Mar 2522597353931 Dec 24267133364030 Sep 2422696363930 Jun 2418559363831 Mar 2413924333331 Dec 2393-11302730 Sep 23990252230 Jun 2310411201631 Mar 2310314201631 Dec 2210217201530 Sep 229026161330 Jun 227835131131 Mar 227228121131 Dec 216522111130 Sep 21646141330 Jun 2163-11171431 Mar 2162-9181431 Dec 2061-8191430 Sep 2064-7211430 Jun 2067-7241531 Mar 2065-16301531 Dec 1962-24351530 Sep 1956-28391430 Jun 1950-31421431 Mar 1958-24461231 Dec 1866-18511030 Sep 1869-20521030 Jun 1873-2354931 Mar 1870-2850931 Dec 1768-3246930 Sep 1768-1838930 Jun 1769-431931 Mar 1769823831 Dec 16681916730 Sep 167018131030 Jun 167216101331 Mar 1666132161831 Dec 1561248232330 Sep 15602412623양질의 수익: COPNZ 은(는) 현재 수익성이 없습니다.이익 마진 증가: COPNZ는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: COPNZ는 수익성이 없지만 지난 5년 동안 연평균 16.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 COPNZ의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: COPNZ은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(16.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: COPNZ는 현재 수익성이 없으므로 자본 수익률이 음수(-1.08%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/21 08:15종가2026/08/17 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cosmo N.V.는 11명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Estelle BétriseyBerenbergLaura HindleyBerenbergKerry HolfordBerenberg8명의 분석가 더 보기
Reported Earnings • Jul 29First half 2026 earnings released: €0.28 loss per share (vs €0.13 loss in 1H 2025)First half 2026 results: €0.28 loss per share (further deteriorated from €0.13 loss in 1H 2025). Revenue: €50.2m (down 2.9% from 1H 2025). Net loss: €4.75m (loss widened 137% from 1H 2025). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
공고 • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
공고 • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025
공고 • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공고 • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024
공고 • Aug 13Cosmo Pharmaceuticals Reports 12-Month Phase 3 Results for Clascoterone 5% Topical Solution in Male Androgenetic AlopeciaCosmo Pharmaceuticals reported recent Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia. According to Cosmo Pharmaceuticals, the 12-month results from its SCALP 1 and SCALP 2 Phase 3 program showed a safety and tolerability profile comparable to vehicle and continued hair growth in patients who remained on treatment through one year. The company reported a statistically significant 2.39-fold improvement in target area hair count among patients who stayed on clascoterone for the full 12 months, compared with those who received the drug for six months and were then switched to vehicle. The program enrolled 1,465 men across 51 centers in the United States and Europe. Androgenetic alopecia, or male pattern hair loss, is the most common cause of hair loss in men. Cosmo reports that it affects roughly 40% of men worldwide and about 65 million men in the United States, yet the category has seen limited pharmaceutical innovation for decades. Clascoterone is designed to locally inhibit androgen receptor signaling in the scalp, targeting one of the biological drivers of follicle miniaturization. According to Cosmo, if approved it would be the first treatment with a novel mechanism of action for male androgenetic alopecia in more than 30 years. Clascoterone is the same active ingredient used in Winlevi, an approved topical acne treatment, which gives the molecule an established dermatologic safety record. The one-year findings come from an extension phase with a specific structure. Only patients who reported a positive response on the study's patient-reported outcome survey during the first six months continued into the second six-month period, where they were re-randomized to stay on clascoterone or switch to vehicle. That design is common in long-term dermatology trials and is consistent with FDA guidance on evaluating durability, but it means the 12-month results describe patients who had already shown a response rather than everyone who started treatment. Cosmo has said it is preparing regulatory submissions, with a U.S. FDA filing planned for early 2027, and intends to submit the full dataset for peer-reviewed publication and presentation at dermatology meetings.
Reported Earnings • Jul 29First half 2026 earnings released: €0.28 loss per share (vs €0.13 loss in 1H 2025)First half 2026 results: €0.28 loss per share (further deteriorated from €0.13 loss in 1H 2025). Revenue: €50.2m (down 2.9% from 1H 2025). Net loss: €4.75m (loss widened 137% from 1H 2025). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.
공고 • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.
공고 • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
공고 • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.
공고 • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).
공고 • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.
공고 • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025
공고 • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
공고 • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.
공고 • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.
New Risk • Mar 24New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin).
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공고 • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024
공고 • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024
공고 • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.
Reported Earnings • Jul 28First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 24Upcoming dividend of €1.05 per share at 2.0% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%).
Reported Earnings • Mar 25Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021)Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
공고 • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CHF42.90, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.
Reported Earnings • Aug 02First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Executive Departure • Jun 04Non-Executive Director Hans Tanner has left the companyOn the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.
Reported Earnings • Mar 27Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 06New 90-day high: CHF87.80The company is up 10.0% from its price of CHF79.90 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 11% over the same period.
공고 • Dec 04Cosmo Pharmaceuticals Announces Licence of Lumeblue (Methylene Blue MMX) China Rights to China Medical System Holdings LtdCosmo Pharmaceuticals N.V. announced that it has licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy. CMS is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China. CMS concentrates on innovative products that are global first-in-class or with the best efficacy or best cost-effectiveness in the same class due to their innovative formulations or drug delivery systems, and has built up an innovative pipeline with great market potential and competitive differentiation advantages at relatively high innovation level, covering various therapeutic fields. Meanwhile, CMS has proven and successful experience in drug promotion for over two decades, and established a professional, compliant and efficient academic promotion system. CMS is listed on the Main Board of the Stock Exchange of Hong Kong. CMS will pay Cosmo a USD 5m upon the earlier of (a) the execution of a supply agreement or (b) the forty-fifth (45th) day from the execution of this agreement, plus royalties and potential regulatory and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™.
공고 • Dec 01Cosmo Pharmaceuticals Appoints H. Jurgen Lenz as New Chief Medical OfficerCosmo Pharmaceuticals N.V. announced that Dr. H. Jurgen Lenz, MD, has been appointed Chief Medical Officer starting from December 1st, 2020. Dr. Lenz is a gastroenterologist and is Chief of the Division of Gastroenterology at Scripps Memorial Hospital, La Jolla, CA, USA. He is member of the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE) and American Association for the Study of Liver Diseases (AASLD).
공고 • Nov 24Cosmo Pharmaceuticals N.V. Announces Senior Leadership Changes, Effective January 1, 2021Cosmo Pharmaceuticals N.V. announced two senior leadership changes which will take effect from the 1st of January 2021. Mr. Giuseppe Cipriano, the current COO, will be appointed to the position of Chief People Officer of Cosmo and will take the lead for all aspects related to managing human resources and industrial relations. Mr. Cipriano has been COO since 2001. Mr. Marco Lecchi, the current Head of Internal Audit, will be appointed to the position of Chief Operating Officer. Mr. Lecchi has been with Cosmo since 2001 and served as Deputy CFO since 2007 prior to his appointment as Head of Internal Audit in 2016.
공고 • Nov 19Cosmo Pharmaceuticals Announces Expansion of Agreement with Dr. Falk Pharma for Rifamycin SV MMXCosmo Pharmaceuticals N.V. announced that it has expanded its existing license agreement with Dr. Falk Pharma Gmbh ("Dr. Falk") to include Rifamycin SV MMX in the new 600mg formulation currently tested in the IBS-D indication. Under the agreement with Dr Falk, Cosmo will receive a further &euro2m down-payment plus reimbursement of a portion of the expenses borne for the development of the 600mg formulation plus a supply price which incorporates a high double-digit percentage of sales. Dr. Falk will also bear a portion of the future costs for the ongoing developments. Rifamycin SV MMX 200mg is already approved in the US and EU for the treatment of travelers' diarrhea and it is licensed to Dr. Falk for the EU and other countries and is marketed under the brand name Relafalk®, whereas it is licensed to RedHill BioPharma Ltd. for the US where it is marketed under the brand name Aemcolo®. A Phase II clinical study with Rifamycin 600mg in IBS-D indication is currently ongoing and results are expected by year end.